Cole Friedes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cole Friedes has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Russell Kenneth Hales
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
9 shared publications Todd R. McNutt
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD
7 shared publicationsWei Fu
Division of Biostatistics and Bioinformatics, Johns Hopkins University School of Medicine, Baltimore, MD
7 shared publicationsChen Hu
Division of Biostatistics and Bioinformatics Johns Hopkins University School of Medicine Baltimore Maryland
6 shared publicationsPeijin Han
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
6 shared publicationsSarah Z. Hazell
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
6 shared publications
Latest Publications
- 2 September 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 224
When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials
- 2 September 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 224
When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials
- 26 May 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 324, 304-306
Letter Regarding: RECIST Responses to Radiation in Retroperitoneal Soft Tissue Sarcoma: When and How Often Do They Occur?
- 26 May 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 324, 304-306
Letter Regarding: RECIST Responses to Radiation in Retroperitoneal Soft Tissue Sarcoma: When and How Often Do They Occur?
- 14 May 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 684-696
Training-oriented framework for brachytherapy treatment planning in soft tissue sarcoma
- 14 May 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 684-696
Training-oriented framework for brachytherapy treatment planning in soft tissue sarcoma
- Open Access
- 17 September 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (2) , 305-310
Primary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008
- 17 September 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (2) , 305-310
Open AccessPrimary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008
- Open Access
- 27 April 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 208, 110911
Salvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy
- 27 April 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 208, 110911
Open AccessSalvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy
- Open Access
“Immune System Modulation with Oral Vancomycin in combination with Stereotactic Body Radiotherapy (SBRT) for medically inoperable Early-Stage Non-small Cell Lung Cancer”
We present the results of a randomized, open-label pilot study investigating the combination of oral vancomycin and stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). Our findings highlight vancomycin’s safety, evidenced by the absence of Grade 3 or 4 adverse events, and its potential to enhance the antitumor efficacy of SBRT. The observed enhancement is linked to vancomycin’s modulation of the gut microbiota, which triggers significant metabolic changes and immune activation, thereby contributing to improved progression-free survival (PFS) and overall survival (OS). Patients received vancomycin (125 mg, four times daily for five weeks, starting one week prior to SBRT), which induced restructuring of the gut microbiome and significant changes in the gut metabolome. Key changes included reductions in short-chain fatty acids (SCFAs) and shifts in other immunomodulatory metabolites. These metabolic shifts were associated with the activation of dendritic cells and T cells, creating a pro-inflammatory environment conducive to strengthening SBRT’s antitumor efficacy. The combination of vancomycin and SBRT presents a novel, low-toxicity therapeutic approach for early-stage NSCLC, showing promising initial outcomes. While the results are encouraging, further research with larger cohorts is necessary to verify these findings and elucidate the underlying mechanisms that contribute to the observed clinical benefits. WHAT IS ALREADY KNOWN ON THIS TOPIC: Radiation therapy is a primary treatment for early-stage non-small cell lung cancer and offers excellent local control in early-stage NSCLC, the challenges of regional and distant failures which occur in up to 50% of patients, lead to increased morbidity and mortality. The gut microbiome is increasingly recognized in cancer immunotherapy. RT can induce Immunogenic Cell Death, activating the immune system and promoting abscopal effect to impact untreated lesions. Our previous preclinical studies have shown that antibiotics like vancomycin can modulate these immune effects and enhance RT’s antitumor activity. WHAT THIS STUDY ADDS: This clinical study corroborates our previous preclinical findings by demonstrating the safety of vancomycin and its potential to enhance the antitumor effects of RT, despite the small cohort size. These findings suggest that vancomycin could be strategically used to improve RT outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: Our findings prompt further investigation into this combined treatment in a larger patient cohort to confirm enhanced progression-free survival and overall survival. Exploring the impact on distal recurrences and applying this strategy to more advanced patient stages could significantly influence future research directions and clinical practices. This approach may also guide policy towards integrating microbiome modulation strategies in standard cancer treatment protocols.
Open Access“Immune System Modulation with Oral Vancomycin in combination with Stereotactic Body Radiotherapy (SBRT) for medically inoperable Early-Stage Non-small Cell Lung Cancer”
We present the results of a randomized, open-label pilot study investigating the combination of oral vancomycin and stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). Our findings highlight vancomycin’s safety, evidenced by the absence of Grade 3 or 4 adverse events, and its potential to enhance the antitumor efficacy of SBRT. The observed enhancement is linked to vancomycin’s modulation of the gut microbiota, which triggers significant metabolic changes and immune activation, thereby contributing to improved progression-free survival (PFS) and overall survival (OS). Patients received vancomycin (125 mg, four times daily for five weeks, starting one week prior to SBRT), which induced restructuring of the gut microbiome and significant changes in the gut metabolome. Key changes included reductions in short-chain fatty acids (SCFAs) and shifts in other immunomodulatory metabolites. These metabolic shifts were associated with the activation of dendritic cells and T cells, creating a pro-inflammatory environment conducive to strengthening SBRT’s antitumor efficacy. The combination of vancomycin and SBRT presents a novel, low-toxicity therapeutic approach for early-stage NSCLC, showing promising initial outcomes. While the results are encouraging, further research with larger cohorts is necessary to verify these findings and elucidate the underlying mechanisms that contribute to the observed clinical benefits. WHAT IS ALREADY KNOWN ON THIS TOPIC: Radiation therapy is a primary treatment for early-stage non-small cell lung cancer and offers excellent local control in early-stage NSCLC, the challenges of regional and distant failures which occur in up to 50% of patients, lead to increased morbidity and mortality. The gut microbiome is increasingly recognized in cancer immunotherapy. RT can induce Immunogenic Cell Death, activating the immune system and promoting abscopal effect to impact untreated lesions. Our previous preclinical studies have shown that antibiotics like vancomycin can modulate these immune effects and enhance RT’s antitumor activity. WHAT THIS STUDY ADDS: This clinical study corroborates our previous preclinical findings by demonstrating the safety of vancomycin and its potential to enhance the antitumor effects of RT, despite the small cohort size. These findings suggest that vancomycin could be strategically used to improve RT outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: Our findings prompt further investigation into this combined treatment in a larger patient cohort to confirm enhanced progression-free survival and overall survival. Exploring the impact on distal recurrences and applying this strategy to more advanced patient stages could significantly influence future research directions and clinical practices. This approach may also guide policy towards integrating microbiome modulation strategies in standard cancer treatment protocols.
- 24 November 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 190, 110030
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
- 24 November 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 190, 110030
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
- 21 October 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 118 (5) , 1435-1444
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
- 21 October 2023
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 118 (5) , 1435-1444
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
- 17 September 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 25 (1) , 50-60.e6
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
- 17 September 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 25 (1) , 50-60.e6
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 5 (5) , 944-952
Improving Early Identification of Significant Weight Loss Using Clinical Decision Support System in Lung Cancer Radiation Therapy
PURPOSE: Early identification of patients who may be at high risk of significant weight loss (SWL) is important for timely clinical intervention in lung cancer radiotherapy (RT). A clinical decision support system (CDSS) for SWL prediction was implemented within the routine clinical workflow and assessed on a prospective cohort of patients. MATERIALS AND METHODS: CDSS incorporated a machine learning prediction model on the basis of radiomics and dosiomics image features and was connected to a web-based dashboard for streamlined patient enrollment, feature extraction, SWL prediction, and physicians' evaluation processes. Patients with lung cancer (N = 37) treated with definitive RT without prior RT were prospectively enrolled in the study. Radiomics and dosiomics features were extracted from CT and 3D dose volume, and SWL probability (≥ 0.5 considered as SWL) was predicted. Two physicians predicted whether the patient would have SWL before and after reviewing the CDSS prediction. The physician's prediction performance without and with CDSS and prediction changes before and after using CDSS were compared. RESULTS: CDSS showed significantly better prediction accuracy than physicians (0.73 v 0.54) with higher specificity (0.81 v 0.50) but with lower sensitivity (0.55 v 0.64). Physicians changed their original prediction after reviewing CDSS prediction for four cases (three correctly and one incorrectly), for all of which CDSS prediction was correct. Physicians' prediction was improved with CDSS in accuracy (0.54-0.59), sensitivity (0.64-0.73), specificity (0.50-0.54), positive predictive value (0.35-0.40), and negative predictive value (0.76-0.82). CONCLUSION: Machine learning–based CDSS showed the potential to improve SWL prediction in lung cancer RT. More investigation on a larger patient cohort is needed to properly interpret CDSS prediction performance and its benefit in clinical decision making.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 5 (5) , 944-952
Improving Early Identification of Significant Weight Loss Using Clinical Decision Support System in Lung Cancer Radiation Therapy
PURPOSE: Early identification of patients who may be at high risk of significant weight loss (SWL) is important for timely clinical intervention in lung cancer radiotherapy (RT). A clinical decision support system (CDSS) for SWL prediction was implemented within the routine clinical workflow and assessed on a prospective cohort of patients. MATERIALS AND METHODS: CDSS incorporated a machine learning prediction model on the basis of radiomics and dosiomics image features and was connected to a web-based dashboard for streamlined patient enrollment, feature extraction, SWL prediction, and physicians' evaluation processes. Patients with lung cancer (N = 37) treated with definitive RT without prior RT were prospectively enrolled in the study. Radiomics and dosiomics features were extracted from CT and 3D dose volume, and SWL probability (≥ 0.5 considered as SWL) was predicted. Two physicians predicted whether the patient would have SWL before and after reviewing the CDSS prediction. The physician's prediction performance without and with CDSS and prediction changes before and after using CDSS were compared. RESULTS: CDSS showed significantly better prediction accuracy than physicians (0.73 v 0.54) with higher specificity (0.81 v 0.50) but with lower sensitivity (0.55 v 0.64). Physicians changed their original prediction after reviewing CDSS prediction for four cases (three correctly and one incorrectly), for all of which CDSS prediction was correct. Physicians' prediction was improved with CDSS in accuracy (0.54-0.59), sensitivity (0.64-0.73), specificity (0.50-0.54), positive predictive value (0.35-0.40), and negative predictive value (0.76-0.82). CONCLUSION: Machine learning–based CDSS showed the potential to improve SWL prediction in lung cancer RT. More investigation on a larger patient cohort is needed to properly interpret CDSS prediction performance and its benefit in clinical decision making.